机构:[1]The Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Abdominal Cancer, Medical School, West China Hospital, Sichuan University, Cancer Center, Chengdu, West China, China.四川大学华西医院
Natural Science Foundation
of China (NSFC 81,972,502, 81,902,577, 81,974,398, and 82,172,785),
Research Foundation for the Postdoctoral Program of Sichuan University
(2021SCU12014), and 1.3.5 project for disciplines of excellence,
West China Hospital, Sichuan University (No. ZYJC21020).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类|3 区医学
小类|4 区神经科学
最新[2023]版:
大类|4 区医学
小类|4 区神经科学
第一作者:
第一作者机构:[1]The Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Wang Zilin,Zhu Sha,Tan Sirui,et al.The P2 purinoceptors in prostate cancer[J].Purinergic signalling.2022,doi:10.1007/s11302-022-09874-2.
APA:
Wang Zilin,Zhu Sha,Tan Sirui,Zeng Yuhao&Zeng Hao.(2022).The P2 purinoceptors in prostate cancer.Purinergic signalling,,
MLA:
Wang Zilin,et al."The P2 purinoceptors in prostate cancer".Purinergic signalling .(2022)